The Medical Letter® On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

IN THIS ISSUE (starts on next page)

Important Copyright Message

The Medical Letter[®] publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769

FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call: 800-211-2769

The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 54 (Issue 1385) March 5, 2012

www.medicalletter.org

IN BRIEF

In Brief: Immediate-Release Oxycodone (Oxecta) for Pain

The FDA has approved a new tablet formulation of immediate-release (IR) oxycodone (Oxecta - King) for management of acute and chronic moderate to severe pain.

Oxecta uses a tamper-resistant technology designed to deter oxycodone abuse by injection or nasal snorting. Dissolving the crushed tablet in water or alcohol converts it into a viscous gel mixture, making it difficult to inject. Crushing the tablet and inhaling it through the nose causes burning and irritation. Whether the new formulation will actually prevent abuse of the drug has not been established. *Oxecta* is classified as a Schedule II controlled substance.¹

Table 1. Some IR Oxycodone Tablets		
Drug	Formulations	Cost ¹
<i>Oxecta</i> (King) Oxycodone – generic <i>Roxicodone</i> (Xanodyne)	5, 7.5 mg tabs 5, 10, 15, 20, 30 mg tabs 5, 15, 30 mg tabs	267.00 ² 15.54 48.64
 Wholesale acquisition cost (WAC) of 100 tablets at lowest available strength. Source: PricePointRx[™]. Reprinted with permission by FDB. All rights reserved. ©2012. http://www.firstdatabank.com/support/drug-pric- ing-policy.aspx. Accessed February 24, 2012. Actual retail prices may be higher. Price for 5- and 7.5-mg tablets is the same. 		

In patients who have not been receiving opioid analgesics, the recommended starting dosage of *Oxecta* is 5 to 15 mg every 4 to 6 hours as needed for pain. Oxycodone has no analgesic ceiling, but dosage is usually limited by its adverse effects. Use of similar abuseresistant tablets has been associated with reports of difficulty swallowing the tablets.² *Oxecta* tablets should be swallowed whole and taken with enough water to ensure complete swallowing.

1. Drugs for pain. Treat Guidel Med Lett 2010; 8:25.

 US Food and Drug Administration. Center for Drug Evaluation and Research. Oxecta (oxycodone HCI) tablets. Summary Review. Available at www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed February 24, 2012.

The Medical Letter® On Drugs and Therapeutics

EDITOR IN CHIEF: Mark Abramowicz, M.D. EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D.

ASSISTANT EDITORS, DRUG INFORMATION: Susan M. Daron, Pharm.D.,

Corinne E. Zanone, Pharm.D.

CONSULTING EDITORS: Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D. CONTRIBUTING EDITORS:

Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School Eric J. Epstein, M.D., Albert Einstein College of Medicine Jules Hirsch, M.D., Rockefeller University David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre Richard B. Kim, M.D., University of Western Ontario Hans Meinertz, M.D., University Hospital, Copenhagen Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Jordan W. Smoller, M.D., Sc.D., Harvard Medical School Neal H. Steigbigel, M.D., New York University School of Medicine

Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weil Medical College of Cornell University SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard

ASSOCIATE EDITOR: Cynthia Macapagal Covey EDITORIAL FELLOW: Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical

School

MANAGING EDITOR: Susie Wong ASSISTANT MANAGING EDITOR: Liz Donohue **PRODUCTION COORDINATOR: Cheryl Brown**

EXECUTIVE DIRECTOR OF SALES: Gene Carbona FULFILLMENT & SYSTEMS MANAGER: Cristine Romatowski DIRECTOR OF MARKETING COMMUNICATIONS: Joanne F. Valentino VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

Subscription Services

Mailing Address:

The Medical Letter, Inc. 145 Huguenot St. Ste. 312 New Rochelle, NY 10801-7537

Customer Service:

Call: 800-211-2769 or 914-235-0500 Fax: 914-632-1733 Web Site: www.medicalletter.org

E-mail: custserv@medicalletter.org

Permissions: To reproduce any portion of this issue,

please e-mail your request to: permissions@medicalletter.org

Copyright 2012. ISSN 1523-2859



3 years - \$279. \$49.00 per year for students, interns, residents and fellows in the US and Canada. E-mail site license inquiries to:

1 year - \$98; 2 years - \$189;

Subscriptions (US):

info@medicalletter.org or call 800-211-2769 x315 Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.

